2024-01-31 11:50:06 ET
Teva Pharmaceutical Industries Limited (TEVA)
Q4 2023 Earnings Conference Call
January 31, 2024 8:00 am ET
Company Participants
Richard Francis - President, Chief Executive Officer
Eric Hughes - Executive Vice President, Global R&D, Chief Medical Officer
Eli Kalif - Executive Vice President, Chief Financial Officer
Ran Meir - Head of Investor Relations
Conference Call Participants
Glen Santangelo - Jefferies
Ash Verma - UBS
Jason Gerberry - Bank of America
Umer Raffat - Evercore
David Amsellem - Piper Sandler
Chris Schott - JP Morgan
Balaji Prasad - Barclays
Nathan Rich - Goldman Sachs
Oleksy Soroka - ING
Madison Aron - JP Morgan
Presentation
Operator
Hello and welcome to the fourth quarter and full year 2023 Teva Pharmaceutical Industries earnings conference call. My name is Alex and I’ll be coordinating the call today.
If you’d like to ask a question at the end of the presentation, you can press star followed by one on your telephone keypad. If you’d like to remove your question, you may press star followed by two.
I’ll now hand it over to your host, Ran Meir, Head of Investor Relations. Please go ahead.
Ran Meir
Thank you Alex. Thank you everyone for joining us today. We hope you’ve had an opportunity to review our press release, which was issued earlier this morning. A copy of this press release, as well as a copy of the slides being presented on this call can be found on our website at tevapharm.com.
Please review our forward-looking statement on Slide No. 2. Additional information regarding this statement and our non-GAAP financial measures is available on our earnings release and in our SEC Forms 10-K and 10-Q.
To begin today’s call, Richard Francis, Teva’s CEO will provide an overview of Teva’s 2023 full year results and business performance, recent events, and our focus and priorities going forward, then Dr. Eric Hughes, our Head of R&D and Chief Medical Officer will discuss progress on our innovative pipeline. Our CFO, Eli Kalif will follow up by reviewing the fourth quarter financial results in more detail before providing an overview of Teva’s 2024 financial outlook....
Read the full article on Seeking Alpha
For further details see:
Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript